Market Cap 26.42B
Revenue (ttm) 1.70B
Net Income (ttm) -190.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.22%
Debt to Equity Ratio 0.06
Volume 630,655
Avg Vol 1,094,138
Day's Range N/A - N/A
Shares Out 137.25M
Stochastic %K 77%
Beta 1.74
Analysts Strong Sell
Price Target $204.84

Company Profile

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples und...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 980 9190
Address:
13011 McCallen Pass, Building A Suite 100, Austin, United States
JenniferHughes8274
JenniferHughes8274 Oct. 26 at 7:28 PM
$NTRA $CHKP Imminent rally https://stocktwits.com/colindequincey/message/633715093
0 · Reply
jowordsworth
jowordsworth Oct. 26 at 12:09 AM
$NTRA $CHKP High - volume breakout https://stocktwits.com/christmarshall/message/633714972
0 · Reply
IN0V8
IN0V8 Oct. 24 at 7:41 PM
$NTRA BTIG raises target price to $210 from $200
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 5:30 PM
BTIG has adjusted their stance on Natera ( $NTRA ), setting the rating to Buy with a target price of 200 → 210.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 8:20 AM
Enter: $NTRA NOV 21 2025 $190 CALLS Buy in Price: $16.10 - $16.91 Take Profit: $29.62 Stop Bleeding: $14.17 ROI Potential: 84% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Oct. 20 at 7:56 PM
$GH $NTRA $EXAS long all these molecular diagnostics names
2 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Oct. 20 at 3:04 PM
$NTRA LONG with huge breakout
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 11:05 AM
Enter: $NTRA NOV 21 2025 $185 CALLS Buy in Price: $12.50 - $12.50 Take Profit: $20.38 Stop Bleeding: $11.00 ROI Potential: 63% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
G_krupins
G_krupins Oct. 18 at 6:44 PM
$NTRA like the look of this one
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 18 at 2:21 PM
Enter: $NTRA NOV 21 2025 $185 CALLS Buy in Price: $12.50 - $12.60 Take Profit: $19.88 Stop Bleeding: $11.00 ROI Potential: 59% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
Latest News on NTRA
Natera Named to Fast Company's Next Big Things in Tech List

Oct 16, 2025, 8:00 AM EDT - 11 days ago

Natera Named to Fast Company's Next Big Things in Tech List


Can Natera Stock Reach $500?

Sep 15, 2025, 10:10 AM EDT - 6 weeks ago

Can Natera Stock Reach $500?


Natera Provides Update on Patent Litigation with NeoGenomics

Aug 29, 2025, 8:18 AM EDT - 2 months ago

Natera Provides Update on Patent Litigation with NeoGenomics


Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 10:43 PM EDT - 2 months ago

Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript


Natera Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Natera Reports Second Quarter 2025 Financial Results


Natera to Report Its Second Quarter Results on August 7, 2025

Jul 31, 2025, 7:00 AM EDT - 3 months ago

Natera to Report Its Second Quarter Results on August 7, 2025


Natera Announces Medicare Coverage for Signatera™ Genome

Jun 4, 2025, 7:00 AM EDT - 5 months ago

Natera Announces Medicare Coverage for Signatera™ Genome


Natera: The Clues In Q1 Earnings

May 16, 2025, 8:41 AM EDT - 5 months ago

Natera: The Clues In Q1 Earnings


Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:58 PM EDT - 6 months ago

Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript


Natera Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 6 months ago

Natera Reports First Quarter 2025 Financial Results


Natera to Report its First Quarter Results on May 8, 2025

May 1, 2025, 7:00 AM EDT - 6 months ago

Natera to Report its First Quarter Results on May 8, 2025


Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 12:23 AM EST - 8 months ago

Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript


JenniferHughes8274
JenniferHughes8274 Oct. 26 at 7:28 PM
$NTRA $CHKP Imminent rally https://stocktwits.com/colindequincey/message/633715093
0 · Reply
jowordsworth
jowordsworth Oct. 26 at 12:09 AM
$NTRA $CHKP High - volume breakout https://stocktwits.com/christmarshall/message/633714972
0 · Reply
IN0V8
IN0V8 Oct. 24 at 7:41 PM
$NTRA BTIG raises target price to $210 from $200
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 5:30 PM
BTIG has adjusted their stance on Natera ( $NTRA ), setting the rating to Buy with a target price of 200 → 210.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 8:20 AM
Enter: $NTRA NOV 21 2025 $190 CALLS Buy in Price: $16.10 - $16.91 Take Profit: $29.62 Stop Bleeding: $14.17 ROI Potential: 84% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Oct. 20 at 7:56 PM
$GH $NTRA $EXAS long all these molecular diagnostics names
2 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Oct. 20 at 3:04 PM
$NTRA LONG with huge breakout
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 11:05 AM
Enter: $NTRA NOV 21 2025 $185 CALLS Buy in Price: $12.50 - $12.50 Take Profit: $20.38 Stop Bleeding: $11.00 ROI Potential: 63% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
G_krupins
G_krupins Oct. 18 at 6:44 PM
$NTRA like the look of this one
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 18 at 2:21 PM
Enter: $NTRA NOV 21 2025 $185 CALLS Buy in Price: $12.50 - $12.60 Take Profit: $19.88 Stop Bleeding: $11.00 ROI Potential: 59% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
VT_MBA
VT_MBA Oct. 17 at 5:54 PM
$NTRA - Ready for breakout
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 16 at 10:08 PM
Enter: $NTRA NOV 21 2025 $180 CALLS Buy in Price: $13.90 - $15.10 Take Profit: $25.16 Stop Bleeding: $12.23 ROI Potential: 81% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
MD109
MD109 Oct. 16 at 3:54 PM
$PSNL Personalis is still very under the radar and the MRD opportunity isn’t fully appreciated by Wall Street. This is going to change. Again, I am a physician and have been studying the ctDNA (liquid biopsy) opportunity for many years. Personalis will reach $50 per share, then eventually break through $100 the same way $NTRA did once Signatera gained reimbursement and sales traction. NeXT Personal is a superior product and I believe $TEM will prove to be a phenomenal commercial partner with potential triple digit sales growth of NeXT Personal. Next year will also be exciting as Colorectal cancer moves closer to reimbursement. Then there is eventual overseas expansion but we’ll save that discussion for a later date. I clearly believe that those who hold $PSNL shares long term will build substantial wealth. But more importantly, Personalis investors are strongly supporting a company whose platform will save and extend the lives of so many people. Hold your shares tight.
2 · Reply
WAJeff
WAJeff Oct. 16 at 1:48 PM
0 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Oct. 16 at 1:46 PM
$GH sold GRAL a while back but still long this and $NTRA in this space
0 · Reply
Doozio
Doozio Oct. 16 at 12:10 PM
$NTRA chop chop huckleberries…. if only they wud give a 🪧. 🐒🍌🧠⏰♾️
0 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Oct. 16 at 12:07 PM
$NTRA on verge of YUGE breakout. Long
0 · Reply
JFDI
JFDI Oct. 15 at 5:37 PM
$NTRA about as pretty as it gets.
0 · Reply
MD109
MD109 Oct. 15 at 3:56 PM
$PSNL I was an early investor in $NTRA at their IPO. Their prenatal testing platform was great, but I was more interested in the oncology tech that they were developing. It was early days and the “liquid biopsy” market for MRD was basically nonexistent. At that time you didn’t hear very much about MRD/surveillance monitoring at medical conferences. The market was so immature and the data just wasn’t there yet. Fast forward 6 years - MRD and liquid biopsy in general is now front and center at medical conferences. The market is starting to mature although still likely less than 5% penetrated in the US. Signatera is firing on all cylinders for Natera. When $PSNL receives Medicare reimbursement for multiple indications, Tempus will slam on the gas and growth will be explosive. The market pull is already very strong with only minimal sales push (60% quarter over quarter). Over 600 physicians already ordering with 98% retention. Plenty of cash and no debt. Hold onto your shares.
2 · Reply
RockyMontana
RockyMontana Oct. 15 at 5:04 AM
$PSNL break new high earlier than $NTRA 🤔
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 14 at 4:27 PM
Enter: $NTRA NOV 21 2025 $175 CALLS Buy in Price: $12.35 - $14.20 Take Profit: $28.40 Stop Bleeding: $10.87 ROI Potential: 130% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 2:08 PM
Canaccord Genuity has adjusted their stance on Natera ( $NTRA ), setting the rating to Buy with a target price of 200.
0 · Reply